Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: Clin Cancer Res. 2014 Mar 17;20(10):2783–2792. doi: 10.1158/1078-0432.CCR-13-2364

Figure 2.

Figure 2

A, The plot of bevacizumab Vnormalized (weight normalized volume of distribution from parameterization [B]) versus total body weight (TBW) implies an apparent non-linear relationship between TBW and Vnon-normalized. In cases of extreme body weight, the Vnormalized of bevacizumab was up to 53% lower (BMI > 97th percentile) or up to 32.1% higher (BMI < 3rd percentile) than the population median value. B, The trend in the scatterplot of CL versus BMI percentile further confirms that body composition is a key determinant of pharmacokinetic interindividual variability when bevacizumab is dosed on a TBW-based regimen.